VC Roundup: NuPathe IPO, no more DreamIt Ventures - Technical.ly Philly

Growth

Aug. 17, 2010 8:50 am

VC Roundup: NuPathe IPO, no more DreamIt Ventures

Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-based private equity firms and the companies they fund. Subscribe to the roundup as an email newsletter. If you have any VC-related news to pass along to us, please drop us a line. DEFINITE READS Later today, look out for the emerging details about Philly […]

Welcome to the VC Roundup, where we’ll parse through venture capital news related to Philadelphia-based private equity firms and the companies they fund. Subscribe to the roundup as an email newsletter. If you have any VC-related news to pass along to us, please drop us a line.

DEFINITE READS

Later today, look out for the emerging details about Philly Mag’s story on Guggenheim Ventures.

Technically Philly wasn’t the only publication to write about DreamIt Demo Day, a handful of other publications also weighed in. In a guest post by DreamIt partner Mike LevinsonTechCrunch takes a very black and white approach offering short paragraphs about every company. PhillyInc looks at DreamIt in perspective of the larger economic climate and the Philadelphia Business Journal focuses more on Startl’s relationship with DreamIt. Of course, you can always look at our three-post Demo Day preview series, our awards post for Demo Day and our collection of videos and pictures from the big day. The DreamIt companies are packing up a leaving the Science Center this week.

MIGHT BE WORTH YOUR TIME

Thanks, in part to an investment by Radnor-based Cross Atlantic Capital, mobile software company Mobile Aware is now breaking even. XACP was part of a $3 million round. The firm also has offices in Ireland and Scotland.

Advertisement

We managed to dig up the documents for NuPathe’s IPO filing. Our liberal arts brains hurt just looking at the thing.

GIVE A GLANCE

It looks like Facebook is eyeing First Round Capital company Hot Potato for an acquisition.

Quaker BioVentures and Novitas Capital were part of a $32 million Series C round in TerraLogic, a company that makes cancer treatment drugs.

In case you were wondering, Saul Richter, the founder of Emerald Stage2 Ventures, can afford a $300,000 condo.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

Sign-up for daily news updates from Technical.ly Philadelphia

Do NOT follow this link or you will be banned from the site!